Asset
Acetaminophen
Revenue
No revenue reported in loaded filings.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06019728 | phase4 | completed | 2023-11-10 | 2024-10-25 | Sanofi | A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme |
| NCT02583594 | phase1 | completed | 2015-12-06 | 2016-03-01 | Genzyme, a Sanofi Company | A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis |
| NCT03368664 | phase3 | terminated | 2017-10-23 | 2021-05-04 | Genzyme, a Sanofi Company | A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT |
| NCT05704049 | phase2 | active_not_recruiting | 2023-04-05 | 2025-12-22 | Sanofi | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma |
| NCT06356571 | phase2 | recruiting | 2025-03-17 | 2027-01-08 | Sanofi | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 018458 | NDA | SANOFI AVENTIS US LLC |
Marketed products (1)
- TALACEN